BioRestorative Therapies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

BioRestorative Therapies wird ein Gewinn- und Umsatzwachstum von 50.1% bzw. 76.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 47.1% pro Jahr wachsen soll.

Wichtige Informationen

57.9%

Wachstumsrate der Gewinne

52.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	34.8%
Wachstumsrate der Einnahmen	77.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:9OF - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3	-20	N/A	N/A	2
12/31/2025	3	-16	N/A	N/A	2
12/31/2024	1	-13	N/A	N/A	2
6/30/2024	0	-4	-7	-7	N/A
3/31/2024	0	-5	-6	-6	N/A
12/31/2023	0	-10	-7	-6	N/A
9/30/2023	0	-15	-7	-6	N/A
6/30/2023	0	-17	-7	-7	N/A
3/31/2023	0	-16	-7	-7	N/A
12/31/2022	0	-13	-6	-6	N/A
9/30/2022	0	-35	-6	-5	N/A
6/30/2022	0	-34	-5	-5	N/A
3/31/2022	0	-33	-4	-4	N/A
12/31/2021	0	-44	-3	-3	N/A
9/30/2021	0	-30	-3	-3	N/A
6/30/2021	0	-26	-3	-3	N/A
3/31/2021	0	-19	-2	-2	N/A
12/31/2020	0	-11	-2	-2	N/A
9/30/2020	0	-7	-3	-3	N/A
6/30/2020	0	-11	-4	-4	N/A
3/31/2020	0	-18	-5	-5	N/A
12/31/2019	0	-15	-7	-7	N/A
9/30/2019	0	-17	-7	-7	N/A
6/30/2019	0	-15	-6	-6	N/A
3/31/2019	0	-14	-6	-6	N/A
12/31/2018	0	-13	-5	-5	N/A
9/30/2018	0	-11	-5	-5	N/A
6/30/2018	0	-10	-4	-4	N/A
3/31/2018	0	-9	N/A	-4	N/A
12/31/2017	0	-9	N/A	-4	N/A
9/30/2017	0	-10	N/A	-4	N/A
6/30/2017	0	-9	N/A	-4	N/A
3/31/2017	0	-9	N/A	-5	N/A
12/31/2016	0	-9	N/A	-5	N/A
9/30/2016	0	-10	N/A	-5	N/A
6/30/2016	0	-9	N/A	-4	N/A
3/31/2016	0	-9	N/A	-4	N/A
12/31/2015	1	-8	N/A	-3	N/A
9/30/2015	1	-6	N/A	-3	N/A
6/30/2015	1	-6	N/A	-3	N/A
3/31/2015	1	-6	N/A	-3	N/A
12/31/2014	0	-6	N/A	-3	N/A
9/30/2014	0	-6	N/A	-3	N/A
6/30/2014	0	-6	N/A	-3	N/A
3/31/2014	0	-6	N/A	-3	N/A
12/31/2013	0	-6	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 9OF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 9OF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 9OF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 9OFDie Einnahmen des Unternehmens (76.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.1% pro Jahr).

Hohe Wachstumseinnahmen: 9OFDie Einnahmen des Unternehmens (76.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 9OF in 3 Jahren voraussichtlich hoch sein wird

BioRestorative Therapies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2024

Recent updates

Second quarter 2024 earnings released: US$0.50 loss per share (vs US$0.77 loss in 2Q 2023)

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc. to Report Q2, 2024 Results on Aug 13, 2024

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Full year 2023 earnings released: US$3.42 loss per share (vs US$5.11 loss in FY 2022)

New major risk - Shareholder dilution

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting

New major risk - Share price stability

BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Third quarter 2023 earnings released: US$0.64 loss per share (vs US$1.28 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.77 loss per share (vs US$1.29 loss in 2Q 2022)

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

Biorestorative Therapies Inc. Receives License from New York State

BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding

BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100

BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program

First quarter 2023 earnings released: US$1.53 loss per share (vs US$1.37 loss in 1Q 2022)

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial

Full year 2022 earnings released: US$5.11 loss per share (vs US$37.30 loss in FY 2021)

Biorestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to Its Thermostem(R) Program

BioRestorative Therapies Inc. Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem Targeting Polycystic Ovary Syndrome as an Indication

Third quarter 2022 earnings released: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

Second quarter 2022 earnings released: US$1.29 loss per share (vs US$5.11 loss in 2Q 2021)

BioRestorative Therapies, Inc. Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Biorestorative Therapies, Inc. Announces Clinical Trial Contract with Second Site for the Company’S Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (Cldd)

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

First quarter 2022 earnings released: US$1.37 loss per share (vs US$21.45 loss in 1Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc. Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Insider recently bought €240k worth of stock

Full year 2021 earnings released: US$37.30 loss per share (vs US$28.56 loss in FY 2020)

Biorestorative Therapies Announces It Has Initiated Its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

Forecast to breakeven in 2024

High number of new and inexperienced directors

BioRestorative Therapies, Inc. Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$4.99 loss per share (vs US$2.10 loss in 3Q 2020)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken